Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Role of omega-3 fatty acids in cardiovascular disease: the debate continues
Abstract Purpose of Review The omega-3 fatty acids (n3-FAs), eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce …
and docosahexaenoic acid (DHA), have recently undergone testing for their ability to reduce …
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
J Brandts, KK Ray - Nature Reviews Cardiology, 2023 - nature.com
Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia
Abstract Background Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial
lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of …
lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of …
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are risk factors
for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference …
for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference …
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis.
Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and …
Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and …
Broadening the scope of dyslipidemia therapy by targeting APOC3 (apolipoprotein C3) and ANGPTL3 (angiopoietin-like protein 3)
HN Ginsberg, IJ Goldberg - Arteriosclerosis, thrombosis, and …, 2023 - ahajournals.org
The positive relationship between increased levels of circulating triglycerides and
cardiovascular events has been observed for decades. Driven by genetic cohort studies …
cardiovascular events has been observed for decades. Driven by genetic cohort studies …
Lipid lowering therapy: an era beyond statins
T Abdul-Rahman, SMA Bukhari, EC Herrera… - Current problems in …, 2022 - Elsevier
Dyslipidemia, specifically elevated low-density lipoprotein (LDL) cholesterol levels, causes
atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial …
atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial …
Do patients benefit from omega-3 fatty acids?
Abstract Omega-3 fatty acids (O3FAs) possess beneficial properties for cardiovascular (CV)
health and elevated O3FA levels are associated with lower incident risk for CV disease …
health and elevated O3FA levels are associated with lower incident risk for CV disease …
[HTML][HTML] New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins
K Kim, HN Ginsberg, SH Choi - Diabetes & metabolism …, 2022 - synapse.koreamed.org
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular
disease (ASCVD). However, even under optimal statin therapy, a significant residual …
disease (ASCVD). However, even under optimal statin therapy, a significant residual …
Updates in drug treatment of severe hypertriglyceridemia
I Gouni-Berthold, J Schwarz, HK Berthold - Current Atherosclerosis …, 2023 - Springer
Abstract Purpose of Review To provide an insight into the new pharmacological options for
the treatment of severe hypertriglyceridemia (sHTG). Recent Findings sHTG is difficult to …
the treatment of severe hypertriglyceridemia (sHTG). Recent Findings sHTG is difficult to …